Conference Coverage

Survey Spotlights Identification of Dermatologic Adverse Events From Cancer Therapies

Publish date: May 13, 2024

 

FROM AAD 2024

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Less Than 50% of Accelerated Approvals Show Clinical Benefit
MDedge ObGyn
CDC Investigating Adverse Events Related to Counterfeit, Mishandled Botulinum Toxin
MDedge ObGyn
Association Calls For Increased Oversight in Response to Reports of Possibly Counterfeit Botulinum Toxin
MDedge ObGyn
Survey Finds Mental Health Issues Increased After Cosmetic Procedure Complications
MDedge ObGyn
Most Targeted Cancer Drugs Lack Substantial Clinical Benefit
MDedge ObGyn
Adding ACEI to Chemotherapy Does Not Prevent Cardiotoxicity
MDedge ObGyn
PCOS: Laser, Light Therapy Helpful for Hirsutism
MDedge ObGyn
Do Health-Related Social Needs Raise Mortality Risk in Cancer Survivors?
MDedge ObGyn
Can a Risk Score Predict Kidney Injury After Cisplatin?
MDedge ObGyn
New mRNA Vaccines in Development for Cancer and Infections
MDedge ObGyn